业绩总结 - 2022年第二季度收入为5.924亿美元，同比增长18%[8] - 2022年第二季度每股净亏损为19.22美元，主要由于30亿美元的非现金商誉减值费用[8] - 2022年第二季度调整后EBITDA为4670万美元[8] - 2022年第三季度收入预期范围为6亿美元至6.2亿美元，同比增长15%至19%[26] - 2022财年收入预期范围为24亿美元至25亿美元，同比增长18%至23%[26] - 2022年第二季度调整后EBITDA为4671万美元，同比下降48%至33%[26] - 2022年第二季度净亏损为31.01亿美元，包含30亿美元的非现金商誉减值[26] - 2022年第二季度调整后毛利率为69.2%[33] - 2022年第二季度调整后EBITDA利润率为12%[26] 现金流与负债 - 截至2022年6月30日，公司现金、现金等价物及短期投资总额为8.84亿美元[24] - 截至2022年6月30日，公司可转换债务及长期债务总额为15.3亿美元[24] - 2022年截至目前的运营现金流为6100万美元[24] - 2022年截至目前的资本支出及资本化软件开发成本为7600万美元[24] 未来展望 - 2022财年预计调整后EBITDA预期范围为2.4亿美元至2.65亿美元[8] - 2022年第三季度调整后EBITDA预期范围为3500万美元至4500万美元[8] - 2022财年每股净亏损预期范围修订为62.00美元至61.00美元[8] - 2022年第三季度每股净亏损预期范围为0.85美元至0.60美元[8]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) (Address of principal executive office ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|---------------------|-------|----------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | Teladoc. HEALTH | | 9 1Q-22 Quarterly Results | | | | Safe Harbor This presentation contains, and our officers may make, "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements inc ...

Teladoc Health Inc. (NYSE:TDOC) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Patrick Feeley - Head of IR Jason Gorevic - CEO Mala Murthy - CFO Conference Call Participants Lisa Gill - JPMorgan Ryan Daniels - William Blair Sandy Draper - Guggenheim Securities Sean Dodge - RBC Capital Markets Richard Close - Canaccord Genuity Stephanie Davis - SVB Leerink Daniel Grosslight - Citigroup Charles Rhyee - Cowen Jessica Tassan - Piper Sandler Allen Lutz - Bank of America Ge ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 8i or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 04-3705970 (State of incorporation) (I ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|---------------------|-------|---------------------------|-------|-------|-------| | | | | | | | | | | | | | | Teladoc. HEALTH | | 9 4Q-21 Quarterly Results | | | | Safe Harbor This presentation contains, and our officers may make, "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitat ...

Teladoc Health Inc. (NYSE:TDOC) Q4 2021 Results Conference Call February 22, 2022 4:30 PM ET Company Participants Patrick Feeley - VP, IR Jason Gorevic - CEO Mala Murthy - CFO Conference Call Participants Charles Rhyee - Cowen Daniel Grosslight - Citi David Larsen - BTIG George Hill - Deutsche Bank Jailendra Singh - Credit Suisse Jessica Tassan - Piper Sandler Lisa Gill - JPMorgan Dev Weerasuriya - Berenberg Richard Close - Canaccord Genuity Ryan MacDonald - Needham Ryan Daniels - William Blair Sean Dodge - ...

| --- | --- | --- | |-----------------------------------|----------------------------|-------| | | | | | Teladoc.. HEALTH | 00000000 | | | J.P. Morgan Healthcare Conference | 00000000 00000000 00000000 | | | Jason Gorevic, CEO January 2022 | 00000000 00000000 OOOOOOOO | | This presentation contains, and our officers may make, "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) 2 Manhattanville Road, Suite 203 P ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|---------------|-------|-------|---------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | Teladoc. | | | 9 3Q-21 Quarterly Results | | | | Safe Harbor This presentation contains, and our officers may make, "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without ...